GLP-1 (Semaglutide)

Description

GLP-1 is Genefyx’s designation for semaglutide, a long-acting synthetic analog of glucagon-like peptide-1, one of the incretin hormones the gut releases after eating. It is a GLP-1 receptor agonist – a molecule shaped to bind and activate the GLP-1 receptor, a key node in the system that links nutrient sensing to insulin secretion and appetite signaling.

As an incretin mimetic, semaglutide is studied for how GLP-1 receptor activation enhances glucose-dependent insulin release, slows gastric emptying, and engages satiety circuits – the reference pharmacology behind an entire class of modern metabolic research molecules. Genefyx supplies it as a research reference material only, mass-spec verified with a certificate of analysis, and it is not intended for human or animal consumption.

How it works

Incretin mimetic — activates GLP-1 receptors to enhance glucose-dependent insulin secretion, slow gastric emptying, and increase satiety.

Research context

The reference GLP-1 class behind modern metabolic and weight research. Branded by Genefyx as “GLP-1.”

Handling

Lyophilized powder. Certificate of analysis, ≥99% purity.

Research use only. Not for animal or human consumption. Not approved or evaluated by the FDA — not a drug, supplement, or therapy. Price shown is a placeholder pending final pricing.